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Abstract
Background: Recently genome-wide association studies identified that NCAN rs2228603 polymorphism was
associated with non-alcoholic fatty liver disease (NAFLD) mainly in subjects of European ancestry. While no
research have been conducted to demonstrate the relationship between NCAN rs2228603 and NAFLD in
Chinese Han adults. The aim of this study was to investigate whether NCAN rs2228603 is associated with
NAFLD in Chinese population.
Methods: Gene NCAN rs2228603 was genotyped in 182 patients with NAFLD and 195 healthy controls. The
expression of NCAN was tested according to polymerase chain reaction analysis (PCR) and serum lipids were
performed by biology techniques.
Results: No significant difference was found in genotype and allele frequencies of NCAN rs2228603 between
the NAFLD group and the controls (P > 0.05). Subjects with the NCAN rs2228603 CT genotype showed a
higher level of alkaline phosphatase (AKP) (P = 0.017) and a higher high-density lipoprotein (HDL) (P < 0.05).
Conclusions: Our study for the first time identified that the gene NCAN rs2228603 is not a risk factor for the
incidence of NAFLD in Chinese population. Also we found the dual and opposite role of T variant in
protecting liver with a higher level of HDL and conferring risk for liver damage with a higher level of AKP.
Trial registration: Chinese Clinical Trial Register.gov Identifier: ChiCTR-ROC-15006447.
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Background
Non-alcoholic fatty liver disease (NAFLD), a hepatic
manifestation of metabolic syndrome, is an emerging pub-
lic health concern which is prevalent in individuals with
metabolic derangements including obesity, insulin resist-
ance, and diabetes mellitus [1, 2]. As a common chronic
liver disease, its spectrum ranged from simple steatosis,
non-alcoholic steatohepatitis (NASH), fibrosis/cirrhosis
and hepatocellular carcinoma [3, 4]. NAFLD is predicted
to be the main course for liver disease world-wide by 2020
[5]. Epidemiologic studies showed a prevalence of about
20~30% in Western countries [6, 7] and 12~15% in China
depending on population and investigative methods [8],
which was similar to some previous studies [9–11].
NAFLD prevalence was confirmed by variety of tools,
which led to the difference. Moreover, In some areas of
China where obesity is more common, which will con-
tinue to grow in a setting of increasing rates of NAFLD
and other metabolic syndrome [12]. Recently, patients
with NAFLD exhibited a high and rising mortality rate
[13, 14]. The most frequent causes of death are repre-
sented by liver-related diseases, cardiovascular disease and
malignantneoplasms [15]. It is considered that the main
course of the death in patients with NAFLD is from cor-
onary events [16–18]. Cardiovascular disease accounted
for about 25% deaths in patients with NAFLD [19, 20].
The pathogenesis of NAFLD is still a complex disorder
and multifaceted process which remains under investiga-
tion. Host genetics are considered as the significant factor
for the formation and development of NAFLD [21].
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Genome-wide association studies had assessed the correl-
ation between NCAN and NAFLD among different ethnic
groups [14, 22].
NCAN contains at least 20 genes in a 500 kb region
on chromosome 19p13 and expresses neurocan, a
chondroitin sulphate proteoglycan that thought to be
involved in celladhesion and migration in the nervous sys-
tem [23–26]. Interestingly, Nischalke’s study showed
NCAN is not only expressed in neuronal tissue, but
also in the liver [27–29]. Studies found that the SNP
rs2228603 in the NCAN gene, resulting in an amino
acid exchange (proline to serine) at position 92, was
strongly related to the plasma low-density lipoprotein
(LDL) and triglyceride (TG) levels [26]. NCAN is used
to be recognized just that the central nervous system
(CNS) is an important regulator of peripheral glucose
and triglyceride metabolism. More studies have dem-
onstrated that SNP rs2228603 was associated with
hepatic steatosis [23, 30]. However, NCAN rs2228603
has been involved in a few studies on NAFLD among
Asian. A recent study showed that SNP in NCAN
was related to the higher level of ALT in Indian sub-
jects [31]. However, Lin et al. studies showed NCAN
was not a risk factor for NAFLD in obese Taiwanese
children [32]. There is no research conducted be-
tween the polymorphism of NCAN and NAFLD in
Chinese Han adults. The aim of this study was to in-
vestigate whether NCAN rs2228603 is associated with
NAFLD in Chinese population.
Methods
Subjects
This study was performed in accordance with the princi-
ples of declaration of Helsinki and its appendices [33]
and approved by the ethical committee of Qingdao mu-
nicipal hospital (Qingdao, China). All patients had pro-
vided written informed consent before participation in
the study.
We selected a total of 377 unrelated adult subjects
from August 2012 to August 2015, including 182 pa-
tients of different genders and different ages (85 males,
97 females,) diagnosed with NAFLD and 195 healthy
controls matched for genders and ages (88 males, 107
females,) who underwent B-type ultrasonography. We
collected subjects from the department of gastroenter-
ology and the medical center of Qingdao municipal
hospital. All individuals were unrelated and ethnically
Han Chinese adults. The diagnosis of NAFLD was
made by ultrasonic imaging according to EASL and
AASLD criteria. Other causes of liver disease were ex-
cluded, including increased alcohol intake (>210/140 g/
week for males/females), as confirmed by at least one
family member or friend and carboxydesialylated trans-
ferrin determination, viral and autoimmune hepatitis,
hereditary hemochromatosis, andalphal-antitrypsin de-
ficiency [11]. The healthy controls were confirmed
using general laboratory examinations and medical ex-
aminations at the same hospital.
Biochemical parameters
We collected venous blood samples after a 12-h over-
night fast from all participants. The following data for
each subject was obtained: height, body weight, waist
circumference and hip circumference. Total cholesterol
(TC), Triglyceride (TG), high-density lipoprotein (HDL)
and low-density lipoprotein (LDL) were measured by
routine enzymatic methods. Serum concentrations of
gamma-glutamyltranspeptidase (GGT), Total bilirubin
(TBIL), alkaline phosphatase (AKP), glucose (GLU), Uric
acid (UA), alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were tested with available stan-
dardized methods. Environmental factors were excluded
in the study.
Genotyping
Genomic DNA was isolated from peripheral blood using
purification kit (BioTeke, Biotechnology, Beijing, China)
according to the manufacturer’s instructions. After ex-
traction, the genomic DNA was stored at −20 °C before
use. Genotyping for NCAN (rs2228603) was performed
by polymerase chain reaction (PCR) using the following
primers for NCAN polymorphism: 5′-TGGCATCGT-
GATGGACTCC-3′, 5′-AATGTCACGCACGATTTCC
C-3′. PCR amplification was performed under the fol-
lowing conditions: 10 min at 95 °C, then 50 cycles before
denaturation at 94 °C for 1 min, annealing at 60 °C for
1 min and elongation 1 min at 70 °C. Direct DNA se-
quencing, the ABI Prism sequence detection system
ABI3730 (Foster city, CA, USA), was taken for the assay
of NCAN genotypes. The average genotype call rate was
>95% and the genotype concordance rate of blind repli-
cates was >99%.
Statistical analysis
Statistical analysis was carried out using SPSS Statistics
software version 17.0 (SPSS Inc. Chicago, IL, USA).
Genotype and alleles were obtained using chi-square test
and the χ2 test was applied to assess DNA distributions
between NAFLD patients and the controls. The baseline
characteristics of participants were presented as mean ±
standard deviation. The differences in characteristics be-
tween different groups were tested by the Student’s t
test, paired samples t test or χ2 test. Logistic regression
analysis was performed to estimate the association of
polymorphism with NAFLD. A P value < 0.05 was con-
sidered statistically significant.
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Results
Clinical characteristics of the participants
We investigated 182 NAFLD patients and 195 controls
matched for age (P = 0.000) and gender (P = 0.759).
Table 1 showed the clinical characteristics and serum
lipid levels of the subjects. Compared to the controls,
NAFLD patients showed increased age, weight, Waist
circumference, Hip circumference, serum ALT, AST,
GGT, AKP, GLU, UA, TG, TC and LDL, however the
level of HDL decreased. These results had significant
differences.
NCAN rs2228603 genotypes and allele distribution
The genotypes distribution of the NCAN rs2228603 cor-
responded to the Hardy-Weinberg equilibriumin in
NAFLD and control groups (PNAFLD =0.179; Pcontrol
=0.101, respectively). To ensure the accuracy of genotyp-
ing, DNA sequencing was repeated in 150 subjects for
reverse sequencing. Distribution of NCAN genotypes
was shown in Table 2, which demonstrated that there
were no significant differences between the patients with
NAFLD and the healthy controls (P > 0.05). The gene
NCAN rs2228603 was not a risk factor in the prevalence
and pathogenesis of NAFLD (OR = 0.832, 95% CI:
0.499–1.386).
Genetic association of NCAN rs2228603 with NAFLD
To evaluate whether the selected SNP influence the la-
boratory parameters, all variants in carriers and non-
carriers were examined. As shown in Table 3, there was
strongly difference in AKP (P = 0.017) between subjects
with allele T and subjects without allele T in overall
series. Meanwhile, a significant difference of HDL (P <
0.05) was observed in all subjects and healthy controls.
However, other serological markers did not reach the
statistical difference (P > 0.05).
Discussion
Recently the gene NCAN on NAFLD has been studied,
however, the results were controversial [23, 34]. The
present study firstly evaluated the association between
rs2228603 polymorphism in the gene NCAN and
NAFLD in Chinese population. Our study selected 182
NAFLD patients and 195 healthy controls to observe the
Table 1 Demographics and clinical characteristics of Patients with NAFLD and Controlsa
Characteristics NAFLD patients (n = 182) Controls (n = 195) p Value
Age, y 46.09 ± 11.59 40.64 ± 11.53 0.000
Gender, Female/Male 97/85 107/88 0.759
Height, cm 167.17 ± 10.55 166.09 ± 6.46 0.237
Weight, kg 74.28 ± 11.44 63.38 ± 11.10 0.000
Waist circumference, cm 92.29 ± 9.29 82.46 ± 8.85 0.000
Hip circumference, cm 103.11 ± 8.21 96.87 ± 8.80 0.000
ALT, U/L 25.63 ± 14.41 19.71 ± 10.49 0.000
AST, U/L 21.90 ± 11.23 19.64 ± 6.46 0.018
GGT, U/L 22.19 ± 9.62 14.88 ± 5.69 0.000
TBIL, umol/L 13.95 ± 6.40 13.36 ± 5.30 0.329
AKP, U/L 68.18 ± 18.35 59.79 ± 13.81 0.000
GLU, mmol/L 5.57 ± 1.79 4.96 ± 1.20 0.000
UA, umol/L 364.42 ± 187.65 301.10 ± 76.82 0.000
TG, mmol/L 1.98 ± 1.78 1.27 ± 1.58 0.000
TC, mmol/L 4.92 ± 0.95 4.64 ± 0.93 0.004
HDL, mmol/L 1.29 ± 0.46 1.48 ± 0.33 0.000
LDL, mmol/L 3.30 ± 0.93 2.94 ± 0.80 0.000
Abbreviation: ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT gamma-glutamyltranspeptidase, TBIL Total bilirubin, AKP alkaline phosphatase,
GLU glucose, UA Uric acid, TG Triglyceride, TC Total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein
aData are presented as Mean ± SD
Table 2 Correlation of the polymorphism in gene NCAN with
risk of NAFLDa





Allele C 0.445 0.505
T 33 41
C 331 349
Abbreviation: NAFLD non-alcoholic fatty liver disease patients
ap: NAFLD patients vs. Control
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correlation between NCAN rs2228603 and NAFLD. We
found no carriers with TT genotype both in NAFLD and
control group, also no significant association of NCAN
rs2228603 with NAFLD was observed in our subjects,
which latter was consistent with some previous findings
[32, 34, 35]. While Speliotes et al. identified that variant
in the gene NCAN was strongly associated with histo-
logic NAFLD and increasing computed tomography
(CT) hepatic steatosis [14]. Rs2228603 is located in exon
3 of NCAN and encodes anon-conservative nonsynon-
ymous mutation (Pro92Ser), which is predicted by the
software tool PolyPhen-2 to alter protein structure and
function [36]. It is plausible that this variant increases
the risk for NAFLD through influencing dietary fat in-
take by modulated by a brain-liver axis [26, 37]. We
characterized the effect of allele T variant in our groups,
which expand further evidence for central control of
liver lipid metabolism.
We found, for the first time, an obvious difference be-
tween variant carriers and non-carriers regarding AKP.
The results showed that NCAN rs2228603 CT genotype
had a higher level of AKP in overall subjects. AKP is a
hydrolase enzyme that commonly used as signal amplifi-
cation in bone metabolism. Matthew’s study showed that
isolated elevated AKP and risk factors for NAFLD should
be evaluated for evidence of significant steatohepatitis
[38]. However, the mechanism of AKP in the pathogenesis
of NAFLD remains unclear and warrants further explor-
ation. The result may provide evidence that carriage of T
allele can elevate AKP to strengthen liver damage.
Meanwhile, we found a protected role of the variant in
lipid metabolism, and observed that the T allele carriers
had a higher serum HDL level than the T allele non-
carriers, whereas no significant correlation was observed
in LDL-cholesterol, total cholesterol and triglyceride
levels with variant carriers. Gorden et al. study found T
allele carriers showed a lower serum LDL-cholesterol,
total cholesterol and triglyceride levels, particularly in
those with NAFLD [23]. Approximately 20~80% NAFLD
patients have dyslipidemia [39]. HDL is negatively re-
lated to the incidence of atherosclerosis and a decreased
level of HDL might indicate the clinical damage to liver
cells, while we could not deny the possible influence of
the elevated HDL-cholesterol on the association between
NCAN and NAFLD among different population. A re-
cent study showed that NCAN is expressed at the lu-
minal side of cholangiocytes and in vesicles of
hepatocytes, which may imply that besides its role in the
nervous system, NCAN may be involved in transport
processes of the liver [27]. Elevated serum HDL-
cholesterol has certain protective effect to the liver; how-
ever, the mechanism is still unclear and further studies
are needed to validate this argument.
Conclusion
In conclusion, this study elucidated that there was no as-
sociation between NCAN rs2228603 polymorphism and
incidence of NAFLD in Chinese population for the first
time. The NCAN rs2228603 T-allele significantly affects
serum AKP and HDL. We can assume that NCAN
Table 3 Analysis of clinical characteristics in NCAN (rs2228603 C/T) carriers and non-carriers of the study populationa
Characteristic Overall series NAFLD patients Controls
Carriers Non-carriers P Carriers Non-carriers P Carriers Non-carriers P
Age, y 44.74 ± 11.20 42.91 ± 12.01 0.234 48.58 ± 10.69 45.54 ± 11.74 0.174 41.66 ± 10.74 40.36 ± 11.75 0.524
Female/male 45/29 200/103 0.401 14/19 83/66 0.166 31/10 117/37 0.961
Height, cm 167.35 ± 7.76 166.43 ± 8.89 0.416 168.45 ± 8.20 166.89 ± 11.00 0.441 166.46 ± 7.36 166.00 ± 6.22 0.682
Weight, Kg 68.41 ± 11.77 68.70 ± 12.67 0.857 71.39 ± 10.34 74.91 ± 11.61 0.110 66.00 ± 12.41 62.69 ± 10.60 0.123
ALT, U/L 22.43 ± 12.41 22.60 ± 12.99 0.920 24.55 ± 12.09 25.87 ± 14.90 0.633 20.73 ± 12.55 19.44 ± 9.90 0.483
AST, U/L 20.68 ± 8.04 20.75 ± 9.40 0.953 20.45 ± 5.84 22.22 ± 12.09 0.415 20.85 ± 9.52 19.32 ± 5.36 0.177
GGT, U/L 17.77 ± 7.631 18.56 ± 8.872 0.479 20.67 ± 8.855 22.52 ± 9.776 0.317 15.44 ± 5.572 14.73 ± 5.735 0.482
TBIL, umol/L 13.43 ± 5.41 13.70 ± 5.97 0.725 12.28 ± 4.94 14.32 ± 6.64 0.097 14.36 ± 5.64 13.09 ± 5.19 0.174
AKP, U/L 65.18 ± 13.75 64.73 ± 17.22 0.017 69.94 ± 16.51 69.34 ± 18.60 0.070 67.95 ± 10.75 60.28 ± 14.50 0.258
Glu. mmol/L 5.04 ± 0.86 5.31 ± 1.66 0.182 5.21 ± 1.09 5.66 ± 1.90 0.194 4.91 ± 0.60 4.98 ± 1.32 0.756
UA, umol/L 307.59 ± 81.35 337.55 ± 156.11 0.111 335.42 ± 98.44 370.85 ± 201.84 0.328 285.20 ± 56.33 305.33 ± 81.03 0.136
TG, mmol/L 1.46 ± 1.28 1.65 ± 1.81 0.381 2.00 ± 1.67 1.98 ± 1.81 0.964 1.03 ± 0.57 1.34 ± 1.75 0.263
TC, mmol/L 4.80 ± 0.92 4.77 ± 0.96 0.825 4.88 ± 0.83 4.93 ± 0.98 0.799 4.73 ± 0.98 4.62 ± 0.92 0.493
HDL, mmol/L 1.47 ± 0.25 1.37 ± 0.44 0.009 1.31 ± 0.26 1.29 ± 0.50 0.861 1.60 ± 0.14 1.44 ± 0.36 0.000
LDL, mmol/L 3.04 ± 0.85 3.13 ± 0.89 0.452 3.18 ± 0.68 3.33 ± 0.98 0.403 2.94 ± 0.96 2.94 ± 0.76 0.985
Abbreviations: ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT gamma-glutamyltranspeptidase, TBIL Total bilirubin, AKP alkaline phosphatase,
GLU glucose, UA Uric acid, TG Triglyceride, TC Total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein
aData are presented as Mean ± SD
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rs2228603 is mainly involved in the progress of NASH
by influence liver damage based on simple steatosis. The
variant may be a protective factor in early stage. Further
studies with large scale of subjects and different ethnicity
are needed to estimate the impact of NCAN rs2228603
on NAFLD. Hopefully, additional research on the role of
NCAN in NAFLD might help to elevate the application
of future therapeutic strategies and interventions.
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